Walleye Capital
TERN

Walleye Capital’s Terns Pharmaceuticals TERN Stock Holding History

Walleye Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,057
Closed -$1.13M – 4977
2025
Q4 		$1.13M Buy
+28,057
New +$648K ﹤0.01% 2335
2025
Q3 		– Sell
-376,559
Closed -$1.4M – 5118
2025
Q2 		$1.4M Sell
376,559
-217,631
-37% -$680K 0.01% 1783
2025
Q1 		$1.64M Buy
594,190
+475,294
+400% +$1.94M 0.01% 1569
2024
Q4 		$659K Sell
118,896
-66,899
-36% -$453K ﹤0.01% 2749
2024
Q3 		$1.55M Buy
+185,795
New +$1.53M ﹤0.01% 2213
2024
Q1 		– Sell
-25,295
Closed -$164K – 5887
2023
Q4 		$164K Sell
25,295
-104,811
-81% -$554K ﹤0.01% 3788
2023
Q3 		$654K Sell
130,106
-215,393
-62% -$1.37M ﹤0.01% 2605
2023
Q2 		$3.02M Buy
+345,499
New +$4.03M 0.01% 1039
2023
Q1 		– Sell
-73,611
Closed -$749K – 4361
2022
Q4 		$749K Buy
73,611
+61,487
+507% +$409K 0.01% 1177
2022
Q3 		$71K Buy
+12,124
New +$45K ﹤0.01% 2521

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Walleye Capital's TERN Position: Q1 2026 in Review

Walleye Capital sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 28,057 shares — an estimated $1.13M sold.

Walleye Capital first reported a position in TERN in Q3 2022 and held it in 10 quarters. The position peaked at $3.02M in Q2 2023. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Walleye Capital reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 28,057 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
  • Walleye Capital first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • Walleye Capital's Terns Pharmaceuticals position peaked at $3.02M in Q2 2023.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.